MIRA Pharmaceuticals Announces Ketamir-2 Outperforms …
1 day ago · MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ...
MIRA says Ketamir-2 outperforms FDA-approved neuropathic …
1 day ago · MIRA Pharmaceuticals announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments Gabapentin and Pregabalin. Ketamir-2, a non-opioid ...
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms …
18 hours ago · About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and ...
MIRA Continues to Post Outstanding Test Results - Yahoo Finance
1 day ago · MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment ...
MIRA Reports Promising Pre-Clinical Results For Ketamir-2 In ...
Aug 24, 2024 · (RTTNews) - MIRA Pharmaceuticals Inc. (MIRA) announced promising pre-clinical results from a recent study assessing its new oral ketamine analog, Ketamir-2, using a rat model of nerve-ligation...
MIRA Pharmaceuticals, Inc. (MIRA) - Yahoo Finance
Get the latest news and updates on MIRA Pharmaceuticals, a preclinical-stage company developing a new synthetic cannabinoid for neuropathic pain and dementia. See press releases, SEC filings,...
Mira Pharmaceuticals Announces Promising Results for MIRA-55 …
Jul 15, 2024 · Mira Pharmaceuticals, a pre-clinical-stage company, announced promising results for MIRA-55, a novel oral marijuana analog, in multiple tests compared to THC. MIRA-55 showed enhanced efficacy, consistency, and safety for potential treatment of …
MIRA Pharmaceuticals, Inc.
Sep 27, 2024 · MIRA is a biotech company developing novel compounds based on ketamine and marijuana for neurologic and neuropsychiatric disorders. Learn about its latest news, preclinical data, and clinical trials for neuropathic pain.
Press Releases - MIRA Pharmaceuticals, Inc.
Aug 12, 2024 · MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms …
1 day ago · MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica).Ketamir-2, a non-opioid, offers tremendous promise for ...
- Some results have been removed